Enjoyed this conversation on the health, economic, and cultural effects of GLP-1s with Adam Conover. Give it a listen if interested!

Our JAMA study explores how a new health equity adjustment will impact hospital performance in Medicare's Value-Based Purchasing program

Top-line: Safety-net hospitals will experience a net + ⬆️ of ≈$30 million in payment adjustments
bit.ly/3xbpovX BIDMC Smith Center

Dr. Dhruv Khullar discusses the trend of hospital acquisition of physician practices in the United States. Listen to the full interview: nej.md/4a5wH7f

Enjoyed this conversation with Stephen Morrissey NEJM on how vertical integration is changing US health care—what we know and, importantly, what we need to know:

podcasts.apple.com/us/podcast/nej…

Hospitals acquiring physician practices has become a dominant trend in American medicine, transforming the delivery of care.

In NEJM, we examine the causes and implications, and propose 3 key questions to inform if and when regulators should intervene: nejm.org/doi/full/10.10…

In this week’s The New Yorker, I write about getting older, how our minds change with time, and what Biden can do to assuage concerns about his age:

Large language models could play an increasingly important role in health care. In new JGIM Journal of General Internal Medicine commentary, Fei Wang Xingbo.WANG and I outline potential use cases but also key limitations and risks, as well as how to mitigate them. Weill Cornell Medicine Population Health Sciences

link.springer.com/article/10.100…

Enjoyed chatting with Ravi Gupta about Ozempic, full-body MRIs, and other big changes in US health care. Check out our conversation The Branch pod here: open.spotify.com/episode/4zZJqD…

The Physicians Foundation Center for the Study of Physician Practice and Leadership is spearheading research that enables physicians and patients to lead healthier lives. Learn more about their mission from director Dhruv Khullar: vimeo.com/890042076

A growing number of companies are offering direct-to-consumer, full-body MRI scans as a preventive screening tool. Should you get one?

In new The New Yorker, I examine the arguments for and against—and what's ultimately at stake:

newyorker.com/science/annals…

🎙ON AIR:

We’re speaking w/ @dhruvkhullar about his The New Yorker piece on Ozempic & UC San Francisco's Dr. Diana Thiara about what we’ve learned about the drug.

❓Have you taken Ozempic or another new weight loss drug? What was your experience?

📻Listen:
kqed.org/forum/20101018…

The new GLP-1 drugs may be the most important health story of the year and the most effective weight-loss treatments in history. In new The New Yorker, I explore the ways in which they will and won't change society in the years to come: newyorker.com/culture/2023-i…

Drugs such as Ozempic and Wegovy are not a cure for obesity, or the stigma associated with it, “but, for many millions of people, our post-Ozempic world will be better than the one we lived in before,” Dhruv Khullar writes. nyer.cm/GjolW8N